Page last updated: 2024-11-06

1-methyluric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-methyluric acid : An oxopurine that is 7,9-dihydro-1H-purine-2,6,8(3H)-trione substituted by a methyl group at N-1. It is one of the metabolites of caffeine found in human urine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID69726
CHEMBL ID793
CHEBI ID68441
SCHEMBL ID235671
MeSH IDM0096497

Synonyms (31)

Synonym
1-methyluric acid
708-79-2
chebi:68441 ,
CHEMBL793
1-methyl-7,9-dihydro-3h-purine-2,6,8-trione
1-methyl-7,9-dihydro-1h-purine-2,6,8(3h)-trione
1-methylurate
einecs 211-905-7
unii-2ws4hq639j
2ws4hq639j ,
7,9-dihydro-1-methyl-1h-purine-2,6,8(3h)-trione
FT-0672361
1-methyl-2,6,8-trihydroxypurine
1h-purine-2,6,8(3h)-trione,7,9-dihydro-1-methyl-
SCHEMBL235671
DTXSID70221063
1-methyl-1h-purine-2,6,8(3h,7h,9h)-trione
W-203591
QFDRTQONISXGJA-UHFFFAOYSA-N
uric acid, 1-methyl-
1-methyl-2,3,6,7,8,9-hexahydro-1h-purine-2,6,8-trione
1-methyluric acid, >=98.0% (hplc)
AKOS027320548
HY-W010031
CS-W010747
1h-purine-2,6,8(3h)-trione, 7,9-dihydro-1-methyl-
FT-0672362
1173022-91-7
Q27136940
1-methyluric acid-13c4,15n3
PD099505

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"In the present study we have investigated the use of caffeine, administered in the form of instant coffee, as a prodrug for 1MX to validate the use of the 1MU:1MX ratio following caffeine administration as a pharmacodynamic measure of oxypurinol effect on xanthine oxidase."( 1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect.
Birkett, DJ; Day, RO; Lillywhite, KJ; Miners, JO; Valente, L, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Dosing with theophylline was used to produce 1MX as an intermediate metabolite in six healthy volunteers."( 1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.
Birkett, DJ; Day, RO; Miners, JO, 1991
)
0.28
" Dosage of each quinolone was 200 mg twice daily for four days, starting three days prior to the theophylline infusion."( Drug-drug interactions affecting fluoroquinolones.
Guelen, PJ; Janssen, TJ; Vree, TB; Wijnands, GJ, 1989
)
0.28
", twice daily for 11 days in a sustained release dosage form."( Enoxacin--a potent inhibitor of theophylline metabolism.
Beckmann, J; Elsässer, W; Gundert-Remy, U; Hertrampf, R, 1987
)
0.27
"Differences in plasma theophylline clearance (ClT) and metabolism between smoking and nonsmoking normal subjects were examined by analysis of plasma and urinary theophylline concentrations and of urinary metabolite concentrations under steady-state oral dosing conditions."( Cigarette smoking and theophylline clearance and metabolism.
Birkett, DJ; Grygiel, JJ, 1981
)
0.26
"The relationship between the plasma oxypurinol (the active metabolite of allopurinol) concentration at the midpoint of each caffeine dosage interval and the decrement in the urinary 1MX to 1MU ratio fitted well by a sigmoid Emax model."( 1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect.
Birkett, DJ; Day, RO; Lillywhite, KJ; Miners, JO; Valente, L, 1997
)
0.3
" After drug-induced hepatitis, a caffeine test might be used to check the total recovery or to choose an adapted dosage of medicines."( Caffeine metabolism differences in acute hepatitis of viral and drug origin.
Bechtel, PR; Bechtel, YC; Brientini, MP; David-Laroche, M; Lelouët, H; Miguet, JP; Paintaud, G,
)
0.13
" This dosage of aciclovir did not change the activity of 7-ethoxyresorufin O-dealkylation, which is represented as CYP1A2 activity."( Lack of effect of aciclovir on metabolism of theophylline and expression of hepatic cytochrome P450 1A2 in rats.
Hasegawa, T; Kato, M; Kimura, M; Nadai, M; Tsunekawa, Y; Ueyama, J; Yasui, K; Yoshizumi, H; Zhao, YL, 2007
)
0.34
"Any sampling interval at least 4 h after caffeine dosing is suitable for NAT2 and XO activity assessments."( Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?
Fuhr, U; Jetter, A; Kinzig, M; Rodamer, M; Sörgel, F; Tomalik-Scharte, D, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
oxopurine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Caffeine Pathway, Pharmacokinetics66
Caffeine Metabolism821
theophylline degradation315
Caffeine and theobromine metabolism011

Bioassays (6)

Assay IDTitleYearJournalArticle
AID54305Tested for antioxidant activity using bovine heart mitochondria and iron(II) / dihydroxy fumaric acid (DHF) at 100 uM1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Long-chain-substituted uric acid and 5,6-diaminouracil derivatives as novel agents against free radical processes: synthesis and in vitro activity.
AID230361Reducing activity to scavenge 10 uM 1, 1-diphenylpicrylhydrazyl (DPPH)1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Long-chain-substituted uric acid and 5,6-diaminouracil derivatives as novel agents against free radical processes: synthesis and in vitro activity.
AID453744Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation by continuous spectrophotometric assay in presence of 150 mM NH4Cl2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID252792Insulin release in rat pancreatic beta-cells after 15 minutes of administration at 1 mM was measured2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells.
AID227566Percent inhibition at 100 uM against peroxidation of methyl linoleate / DMVN in TBA /methanol medium at 40 degree Centigrade1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Long-chain-substituted uric acid and 5,6-diaminouracil derivatives as novel agents against free radical processes: synthesis and in vitro activity.
AID453747Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation by continuous spectrophotometric assay in presence of 10 mM L-glutamine and 0.15 mM 2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (32.84)18.7374
1990's19 (28.36)18.2507
2000's16 (23.88)29.6817
2010's10 (14.93)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.50 (24.57)
Research Supply Index4.41 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index28.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (8.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (2.67%)4.05%
Observational0 (0.00%)0.25%
Other67 (89.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]